Gene marker combination for evaluating etiological control prognosis of hepatic fibrosis and application of gene marker combination

• Main Authors: CHEN WEI, YOU HONG, CHEN SHUYAN, ZHANG WEN, SUN YAMENG
• Format: Patent
• Language: Chinese; English
• Published: 16.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention discloses a gene marker combination for evaluating hepatic fibrosis etiology control prognosis and application thereof. The invention firstly discloses a gene marker combination for evaluating the etiological control prognosis of hepatic fibrosis, wherein the gene marker combination comprises BUB1B, CDC45, CDT1, CHEK1, CLSPN, DEPDC1, E2F8, ECT2, KIF11, KIF18A, KIF4A, KIFC1, MKI67, ORC6, PARPBP, PBK, RRM2 and TOP2A. The invention further discloses application of a detection reagent for the expression level of the gene marker combination in preparation of a kit for evaluating hepatic fibrosis etiology control prognosis. The expression level difference of the gene marker combination can be used for predicting the reversing condition of prognostic hepatic fibrosis of an initially treated patient under long-term etiological control, so that better clinical diagnosis and treatment and supervision management are carried out on the patient, and clinical benefits are expected to be brought to more patien